

# Laboratory Medicine Best Practices: Transparent Methods for Patient-Centered, Evidence-Based Quality Improvement

LABORATORY MEDICINE  
*Best Practices*

ABOUT US

GET INVOLVED

OUR METHODS

OUR FINDINGS



Presented by

**Robert H. Christenson, PhD, DABCC, FACB**

Professor of Pathology, Medical, and Research Technology,  
University of Maryland School of Medicine

**Diana Mass, MA, MT(ASCP)**

Director and Clinical Professor (Retired)  
Clinical Laboratory Sciences Program  
Arizona State University

# Today's Objectives

- Describe differences between AHRQ and LMBP Efforts.
- Discuss the need for the use of evidence based laboratory medicine to insure patient-centered outcomes.
- Describe the LMBP A-6 Cycle that includes published studies and unpublished findings.
- Review the LMBP topic selection process and a pilot study of practices to reduce blood culture contamination rates.
- Note LMPB on-line tutorials to educate laboratory professionals about quality improvement study designs.
- Describe key efforts to sustain the LMBP Initiative and gain support from official bodies.

# LMBP Systematic Review Steps

## ASK

Frame focused question(s) to be answered by the evidence

## ACQUIRE

Identify sources and collect potentially relevant studies

## APPRAISE

Create an evidence base by applying screening and evaluation/ rating criteria

## ANALYZE

Synthesize and rate overall strength of body of evidence (quality, effect size, consistency)

## APPLY

Disseminate findings for review and local application

## AUDIT/ASSESS

# Evidence Based Systematic Reviews

**Medical Test Reviews-AHRQ**

**Laboratory Medicine Best Practices-CDC**



# Medical Test Reviews-AHRQ

## Writing the Report

- Follow a standard template for the overall report:
  - Abstract and Executive Summary
  - Chapter 1. Introduction
  - Chapter 2. Methods
  - Chapter 3. Results
  - Chapter 4. Discussion
- Ordering of subsections may vary but:
  - Should adhere to principles of clarity
  - Should be consistent with key questions
  - May be guided by PICOTS

PICOT(S) = population, intervention, comparator, outcome, time frame, and study design or setting

# Agency for **H**ealthcare **R**esearch **Q**uality

- **M**edical **T**est **R**eviews
- **Test**-A medical test is a kind of medical procedure performed to detect, diagnose, or evaluate disease, disease processes, susceptibility, and determine a course of treatment

## Laboratory **M**edicine **B**est **P**ractices

- Patient-centered, transparent systematic reviews
- **Practices**- Protocols, procedures, policies, techniques, processes, systems, standards, incentives, activities, and interventions that are used to provide healthcare to patients.

# AHRQ Topic Development

- Topic development begins with a claim
  - Testing strategy's impact on health outcome
  - Test's clinical role
  - Potential advantages over existing test or strategy

## LMBP Topic Development

- Topic development begins with:
  - IOM priorities: Safe, Timely, Effective, Efficient, Equitable, Patient-Centered
  - *Evidence*: At least modest; *Outcome measure(s)*: At least one relevant outcome; *Practices*: At least 3 practices affecting performance or outcomes related to a quality issue.



# LMBP

Formulate an Answerable Question  
the PICO system


- **Population (Patient Description)**
- **Indicator (Practice)**
- **Comparator (Control practice)**
- **Outcome (Health-related, Economic)**

# AHRQ


Formulate an Answerable Question  
the PICOT(S) system

- **P**opulation (Description of patients)
- **I**ndicator (test, intervention)
- **C**omparator (**C**ontrol, **G**old Standard )
- **O**utcome (Detect, Diagnose, evaluate)
- **T**ime Frame (**w**hen to test)
- **S**tudy Design or Setting (**R**CT, **E**D)

# US Preventive Services Task Force Analytic Framework



# LMBP Analytic Framework



# Medical Test Review

**Claim: health outcome, clinical role, advantages**

**Do patients having the test  
fare better than similar  
patients who do not have  
the test?**

# Lab Medicine Best Practices

Safe, Timely, Effective, Efficient, Equitable and Patient-Centered

**Do patients at institutions  
using the laboratory medicine  
best practice recommendations  
fare better than similar patients  
where the best practice  
recommendations are not  
implemented?**


# LMBP and Arthur Rubinstein?

A guy once asked pianist Arthur Rubinstein "Pardon me sir, but how do I get to Carnegie Hall?" and Rubinstein replied

- Practice
- Practice
- Practice

# LMBP Systematic Review Methods

## A-6 Cycle





# LMBP

Formulate an Answerable Question  
the PICO system

- **P**opulation (**P**atient **D**escription)
- **I**ndicator (**P**ractice)
- **C**omparator (**C**ontrol practice)
- **O**utcome (**H**ealth-related, **E**conomic)


# LMBP: Form as a Review Question

---

## Example Topic: Communicating Critical Values


**Example Review Question:** For hospitalized patients, what practices are effective for communicating laboratory critical value results in a timely and accurate fashion to the licensed caregiver who can act on them?

# LMBP Analytic Framework



# ACQUIRE: Identify sources and collect potentially relevant studies

---



# ACQUIRE: Identify sources for evidence to address the specific question

---

- Reference Databases ( e.g. Medline AND EMBASE, Cochrane)
- Hand-searching key journals
- Meeting Abstracts or conference proceedings
- Special Databases (grey literature)
- Reference lists and citation searching
- Commentaries (may lead to other sources)
- Contacting Experts (unpublished studies)
- The Internet
- Unpublished studies

## ACQUIRE: Identify sources for evidence to address the specific question

---

- Reference Databases ( e.g. Medline AND EMBASE, Cochrane)
- Hand-searching key journals
- Meeting Abstracts or conference proceedings
- Special Databases (grey literature)
- Reference lists and citation searching
- Commentaries (may lead to other sources)
- Contacting Experts (unpublished studies)
- The Internet
- **Unpublished reports and studies**

# Expert Panels


---

Each topic area Expert Panel have 7-9 panelists:

- 2-3 Work Group members with relevant topic area content expertise
- 2-3 topic area content experts who are not Work Group members
- 1 specialist in evidence review methods
- 2 specialists in laboratory management, including administrative and laboratorian specialties

**Appraise:** Create an evidence base by applying screening and evaluation/ rating criteria

---





# LMBP APPRAISE STEP (A3)

## Process Summary

- **Initial screen** of search results (exclusion criteria)
- **Abstract, standardize and summarize** studies meeting inclusion criteria
- **Evaluate and rate/score**
  - Study quality
  - Effect size
- **Synthesize** into a practice body of evidence

# LMBP APPRAISE STEP (A3)

## Overview

- **Purpose**

Evaluate the search results (published and unpublished) from the ACQUIRE (A2) step to identify and qualify studies for potential inclusion as evidence of practice effectiveness that address the focused review question(s) framed in the ASK (A1) step.

- **Process**

Initial screening of individual published and unpublished search results against LMBP study inclusion and exclusion criteria to full abstraction and evaluation of candidate studies, including rating of study quality and effect size, for a specific practice's evidence base using a minimum of two reviewers


- **Results**

A practice-specific aggregate body of evidence (evidence base) of effectiveness studies for use in the ANALYZE (A4) step, including evaluation of effect size and consistency and meta-analysis using individual study results

# Report search strategy and account for and the sources

---

- Inclusion / exclusion criteria for the topic



# Evidence Summary Table

---

## Quality Domains

---

### Bibliographic Information

- Author (s)
- Yr Published/Submitted
- Publication
- Author Affiliations
- Funding

### Quality Domains Points

2

2

1

3

- Two Abstractors independently review evidence
- Results of abstractions are compared
- Meeting to resolve Abstractor discrepancies

# Appraise

---

## Step 1 – Study Quality Rating

Practice A	Study Characteristics (3 pts)	Practice Characteristics (2 pts)	Outcome Measures (2 pts)	Results (3 Pts)	Overall Study Quality Rating
Study 1	2	2	1	3	8
Study 2	2	1	1	1	5
...					
Study n					

- **Good: 8-10 pts**
- **Fair: 5-7 pts**
- **Poor  $\leq$  4 pts**

# Combine Appraise Steps 1 & 2

## 1 – Study Quality Rating

## 2 – Study Effect Size Rating

Practice A	Study Characteristics (3 pts)	Practice Characteristics (2 pts)	Outcome Measures (2 pts)	Results (3 Pts)	Overall Study Quality Rating
Study 1	2	2	1	3	8
Study 2					
...					
Study n					

Study Ratings	Effect Size
Study 1	Substantial
Study 2	
...	
Study n	

- Good: 8-10 pts
- Fair: 5-7 pts
- Poor  $\leq$  4 pts

- Substantial
- Moderate
- Minimal/None

Study Ratings	Study Quality Rating	Study Effect Size Rating
Study 1	Good	
Study 2	1	2
...		
Study n		


Individual Study Ratings

# Standardize, Summarize and Rate Studies

Practices reducing patient specimen identification errors


Practice:	Study Quality Rating						Effect Size Rating
Evidence	Outcome						Rating
	Study	Practice	Measure	Results	Total	Rating	
Bologna 2002	2	2	2	2	8	Good	Substantial
Hayden et al. 2008	3	2	2	3	10	Good	Substantial
	<b>2</b>	<b>2</b>	<b>2</b>	<b>3</b>	<b>9</b>	<b>Good</b>	<b>Substantial</b>
Sandler et al. 2005	1				3	Poor	n/a
Turner et al. 2003	1				4	Poor	n/a
Zarbo et al. 2009	2				9	Good	Moderate
Unpub A 2009	3				7	Fair	Substantial
U of MN 2009	1				5	Fair	Substantial
U of WA 2009	2				8	Good	Substantial
LBJ 2009	2				8	Good	Substantial

Study characteri  
 Practice description (Maximum = 2)  
 Outcome Measure (Maximum = 2)  
 Results of Study (Maximum = 3)



Good: 8 -10 points  
 Fair: 5-7 points  
 Poor: <=4 points

# LMBP – ANALYZE (A-4): Body of Evidence





# Appraise

## Study Quality Rating

Practice A	Study Characteristics (3 pts)	Practice Characteristics (2 pts)	Outcome Measures (2 pts)	Results (3 Pts)	Overall Study Quality Rating
Study 1					
Study 2					
...					
Study n					

## Study Effect Size Rating

Study Ratings	Effect Size
Study 1	
Study 2	
...	
Study n	

- Good: 8-10 pts
- Fair: 5-7 pts
- Poor ≤ 4 pts

- Substantial
- Moderate
- Minimal/None

	Study Quality Rating	Study Effect Size Rating
Study 1	1	2
Study 2		
...		
Study n		

Individual Study Ratings

# Analyze

## Overall Evidence Rating

Individual Study Quality	Individual Effect Size	Consistency (Yes / No)	Overall Strength Rating	Recommendation
# Good: # Fair:	Substantial	3	4	5
# Good: 1 # Fair:	Moderate 2			
# Good: # Fair:	Minimal / None			
# Good: # Fair:	Adverse			

Individual Study Ratings

Overall Evidence Ratings

# LMBP Expert Panels



- Reach consensus on topic area evidence review quality and effect size rating categories
- Apply and provide feedback on evaluation methods to produce ratings for individual study quality and effect size
- Evaluate individual practices' overall strength of evidence, effect size consistency (i.e., direction and magnitude)
- Develop final draft practice evidence summaries and draft recommendations to be presented to the LMBP Workgroup


# Meta Analysis

## Evaluate Consistency & Standardized Effect Size

### Test Practice Compared to Standard Practice

<u>Study name</u>	Odds ratio	Lower limit	Upper limit
Study 1 (2001)	2.32	1.11	4.87
Study 2 (2000)	1.94	0.79	4.78
Study 3 (2004)	1.78	0.93	3.41
Study 4 (2005)	0.98	0.39	2.47
Study 5 (2002)	0.94	0.34	2.62
Study 6 (2003)	0.32	0.12	0.85
Summary Effect Estimate	1.22	0.70	2.12


### Odds ratio and 95% CI



# Consistency (Yes/No)

## Overall Evidence Rating

Individual Study Quality	Individual Effect Size	Consistency (Yes / No)	Overall Strength Rating	Recommendation
# Good: # Fair:	Substantial	3 Yes / No	4	5
# Good: <b>1</b> # Fair:	Moderate <b>2</b>			
# Good: # Fair:	Minimal / None			
# Good: # Fair:	Adverse			




Statistics for each study

Std diff in means and 95% CI

Study name
Study A (2007)
Study E (2009)
Study B (2007)
Study C (2008)
Study F (2010)
Study D (2009)
Summary effect estimate

Std diff in means	Standard error	Lower limit	Upper limit
0.85	0.11	0.62	1.07
0.64	0.03	0.59	0.69
0.47	0.06	0.36	0.58
0.34	0.06	0.21	0.46
0.07	0.05	-0.04	0.17
-0.28	0.06	-0.40	-0.17
0.34	0.16	0.03	0.66



-1.00 -0.50 0.00 0.50 1.00

Favors Standard Practice      Favors Test Practice

# Overall Strength of Evidence

## Overall Evidence Rating


Individual Study Quality	Individual Effect Size	Consistency (Yes / No)	Overall Strength Rating	Recommendation
# Good: # Fair:	Substantial	<b>3</b> Yes / No	<b>4</b>	<b>5</b>
# Good: <b>1</b> # Fair:	Moderate <b>2</b>			
# Good: # Fair:	Minimal / None			
# Good: # Fair:	Adverse			

Strength Ratings	Combined Evidence Minimum Criteria		
	#Studies*	Effect Size Rating	Quality Rating
High	≥ 3	Substantial	Good
Moderate	≥ 2 or ≥ 3	Substantial Moderate	Good Good
Suggestive (Low)	≥ 1 or ≥ 2 or ≥ 3	Substantial Moderate Moderate	Good Good Fair
Insufficient (Very Low)	All others		

# Laboratory Medicine Best Practices Evidence-Based Recommendations


Recommendation Categories	Definition
<b><i>Recommend</i></b> ('Best Practice')	<b>Consistent</b> and <b>high</b> or <b>moderate</b> overall evidence of effectiveness strength rating of desirable effects
<b><i>No recommendation for or against</i></b>	Insufficient evidence to determine effectiveness
<b><i>Recommend against</i></b>	Consistent and <b>high</b> or <b>moderate</b> overall evidence of effectiveness strength rating adverse effects

# LMBP Evidence-based Recommendation



Workgroup

## Expert Panel



Overall Evidence Rating				
Individual Study Quality	Individual Effect Size	Consistency (Yes / No)	Overall Strength Rating	Recommendation
# Good # Fair	Substantial	3	4	5
# Good # Fair	Moderate			
# Good # Fair	Minimal / None			
# Good # Fair	Adverse			


### Recommendation Categories

- Recommend
- No recommendation for or against
- Recommend against

### Additional Considerations

- Feasibility of implementation
- Economic evaluation
- Applicability to specific care settings
- Associated harms and benefits

# LMBP Systematic Review Methods A-6 Cycle





# Meeting Laboratory Practitioners' Needs

COMMON SCENARIOS THAT REQUIRE  
EVIDENCE-BASED DECISION MAKING

# An Administrative Director wants to request new technology

- Patient specimen identification errors continue to be a major problem despite the implementation of new identification guidelines. The medical center is considering a bar-coding system to reduce patient specimen identification errors.
- The Laboratory Administrative Director is requested to evaluate the benefits of this new technology.

**Question:** How does the Administrative Director determine if this practice (bar coding systems) has been effective in other settings?

# An Emergency Department physician wants the laboratory to improve MRSA testing turn-around-time

---

- Patient admissions with potential infectious conditions are on the rise, and the bed management coordinator needs information in a timelier manner to make room assignments. These patients remain in the ED for an extended period of time until the laboratory results are reported. This creates a longer waiting time for new patients arriving in the emergency department.
- The Microbiology Supervisor is requested to evaluate new tests that may result in an improvement in TAT.

**Question:** How does the Microbiology Supervisor evaluate other tests on the market that will result in effective patient admissions?

# A Diabetes Center Manager wants to change the mode of delivery of care

- The clinicians at a Diabetes Center want to improve patient compliance. They have read that HbA1c is available in a point of care testing (POCT) device and can improve the management of the patient's condition by providing test results at the time of patient consultation and thus improve patient outcomes.
- The Manager is asked to contact the hospital laboratory's Chemistry Supervisor to help evaluate the effectiveness of POCT device in other settings and its potential implementation.

**Question:** How does the Chemistry Supervisor evaluate the evidence on the use of POCT for HbA1c.

# Applying an Evidence-Based Approach to Laboratory Medicine

---


Using evidence to evaluate practice effectiveness can help laboratory professionals and healthcare stakeholders to:

- Determine what practices are effective, for whom and in what settings(s)
- Inform clinical decision making
- Improve patient care and outcomes
- Promote transparency and accountability

# How are Topics Identified?

## Two Groups of Advisors

---



Let's keep the big picture in mind

### Workgroup



"We're getting down to nuts and Bolts"

### Expert Panel

# How Are Topics Identified? Additional Input:

---

- Personnel from LMBP Team (CDC/Battelle)
- Professional Organizations
- Accrediting Agencies
- LMBP Website
- Communications with Laboratory Professionals

# Major Criteria for Topic Selection

---

## Consistent with one or more of IOM Aims

- Patient-centered
- Safe
- Effective
- Efficient
- Equitable
- Timely

Topic represents a practice in the pre- or post-analytic stage of testing process



# Topics Completed in Methods Validation Phases

---

- Reporting critical values
- Patient specimen identification
- Reducing blood culture contamination


# Practices to Reduce Blood Culture Contamination

Example of LMBP A-6 Process Applied

# Clinical Utility

---

- False positive blood cultures lead to errors in clinical interpretation with subsequent consequences:
  - Administration of unnecessary antimicrobial therapy.
  - Performance of additional cultures and other diagnostic tests.
  - Unnecessary hospitalization or extended length of stay (LOS).
  - Increased health care costs.
  - Undue burden on patient.




# LMBP Review Question

---

## ASK

- What interventions/practices are effective at reducing contamination of blood cultures drawn from hospitalized patients?


**ASK - Evidence Review Question:** What interventions/practices are effective at reducing contamination of blood cultures drawn from hospitalized patients?



# ACQUIRE: Search Results

## Published Literature

## Unpublished Assessments




# Venipuncture (versus Intravenous Catheter) Meta-Analysis

## Study name

## Statistics for each study

## Odds ratio and 95% CI

	Odds ratio	Lower limit	Upper limit
McBryde 2005	5.60	3.61	8.69
Norberg 2003	3.46	2.55	4.69
Martinez 2002	2.57	1.12	5.89
Everts 2001	2.12	1.32	3.40
DesJardin 1999	1.88	0.95	3.74
Beutz 2003	1.88	0.88	3.99
Ramsook 2000	1.70	1.01	2.85
	2.63	1.85	3.72



←=Favors Catheter Favors Venipuncture ==→

◆ = Venipuncture summary effect size


**Venipuncture is associated with  
lower blood culture contamination rates**

Odds Ratio = 2.63 (95% CI = 1.85 – 3.72)

Venipuncture is 2.63 times as successful as  
the comparison practice (intravenous catheter)

Boxes proportional to study size.

# Phlebotomy Team Meta-Analysis



Boxes proportional to weights

◆ = Phlebotomy team summary effect size

**Phlebotomy teams are associated with lower blood culture contamination rates.**

Odds Ratio = 2.53 (95% CI = 2.28 – 2.81)


Phlebotomy team is 2.53 times as successful as the comparison practice (without phlebotomy team)



# Prepackaged Prep Kits Meta-Analysis

Study name      Subgroup within study      Odds ratio and 95% CI

		Odds ratio	Lower limit	Upper limit
Trautner 2002	Prep v Usual prx	3.68	1.26	10.74
Weinbaum 1997	Combined	3.51	2.27	5.45
McLellan 2008	Combined	1.03	0.73	1.46
Wilson 2000	Combined	1.03	0.90	1.18
		1.15	1.02	1.30



◆ = Prep kits summary effect size

**Prepackaged prep kits are not associated with lower blood culture contamination rates.**

Odds Ratio = 1.15 (95% CI = 1.02 – 1.30)

Prep kits are about as successful as the comparison practice (without prep kits)

Boxes proportional to weights

# Conclusions

---

Using the LMBP systematic review methods to evaluate the overall strength of evidence of effectiveness for reducing blood culture contamination rates for each practice, the LMBP Blood Culture Contamination Expert Panel and Workgroup recommended the following:

- **Best Practice:** Use of **venipuncture** as the preferred technique for sample collection in the clinical setting, when this option exists
- **Best Practice:** Use of phlebotomy **teams** to collect blood culture specimens
- No recommendation for or against the use of **prepackaged prep kits** (as a best practice).

# Future plans for blood culture topic

---

To continue to disseminate evidence-based practice recommendations to reduce blood culture contamination and improve patient and public health outcomes:

- Application of these practices should continue to be assessed so that these LMBP practice evidence reviews and recommendations can be updated with new study results.
- New evidence reviews and recommendations related to additional practices are needed, and requires acquisition of evidence not currently available

# LMBP Initiative is Fighting These Culprits For You



illustration: Don Smith

# Additional LMBP Pilot Project Findings

---

- New LMBP methods can be used for systematically reviewing and evaluating quality improvement practices
- Quality improvement projects and efforts routinely conducted by laboratories generate relevant data for inclusion in systematic evidence reviews
- Data from quality improvement projects can be used as evidence of practice effectiveness
- Many quality improvement projects fail to meet minimum research standards for good study design

# LMBP Educational Objective

---

- Develop and implement an education / curriculum strategy that familiarizes laboratory professionals with methods for improving the quality of unpublished process improvement / quality assurance studies so that data from these studies are consistently available to inform best practice recommendations.

# LMBP Educational Activity

---

Development of a four-part, self-guided tutorial to:

- Increase awareness about new LMBP evidence-based methodology for conducting systematic evidence reviews, and
- Increase the competence in application of evidence-based principles to quality improvement (QI) projects or research
- Online Module 1 anticipated 1<sup>st</sup> quarter of 2011 at [www.futurelabmedicine.org](http://www.futurelabmedicine.org)

# Building a Curriculum for Evidence-based Laboratory Medicine

---

Solving a clinical problem using an evidence-based approach is a cyclical process that begins with generating an answerable question and ends with assessing the process.

## Core Skills

- Designing outcomes projects
- Formulating answerable questions
- Searching the literature
- Critical appraisal of data
- Interpret analysis of data / meta-analysis
- Writing papers



# Sustainability

# Gerald O'Hara (Thomas Mitchell):

## On Sustainability

Do you mean to tell me, Katie Scarlett O'Hara, that Tara, that land doesn't mean anything to you? Why, land is the only thing in the world worth workin' for, worth fightin' for, worth dyin' for,

because it's the only thing that lasts.

**LMBP systematic reviews get as close the truth as possible. Worth workin' for, worth advocatin' because it's the only thing that lasts.**

# Sustainability

---


- Enlisting partners to support dissemination and uptake of best practices
- Topics in the pipeline
- Suggestions for panelists and feedback on topics: ASM
- Formal recognition of the need for the application of systematic review methods and the use of evidence-based best practices in LM

# LMBP Partner Organizations

---



**American Society for Clinical Laboratory Sciences**



# Sustainability

---

- Enlisting partners to support dissemination and uptake of best practices
- **Topics in the pipeline**
- Suggestions for panelists and feedback on topics: ASM
- Formal recognition of the need for the application of systematic review methods and the use of evidence-based best practices in LM

# Proposed new review topics

---

- **Hemolysis**: What practices are effective at reducing rejection by the clinical laboratory of samples drawn from in-patient and ED patients due to hemolysis as a sample quality issue?
- **Cardiac Biomarker Testing**: Will the adoption of serial point of care testing of cardiac troponin effectively increase accurate myocardial infarction diagnosis, reduce time to treatment, increase appropriate patient disposition and improve patient outcome among ED patients presenting with symptoms suggestive of Acute Coronary Syndrome?
- **Rapid Identification of Bloodstream Infections**: What practices are effective at increasing timeliness of providing targeted therapy for in-patients with diagnosed bloodstream infections to improve clinical outcomes (LOS, morbidity, mortality)?

# Sustainability

---

- Enlisting partners to support dissemination and uptake of best practices
- Topics in the pipeline
- **Suggestions for panelists and feedback on topics: ASM**
- Formal recognition of the need for the application of systematic review methods and the use of evidence-based best practices in LM

## Working Group Roster

Paul Epner  
Principal  
Paul Epner LLC  
1501 Hinman Ave, #7B  
Evanston, IL 60201  
tel: 847-508-2810  
[PEpner@ChicagoBooth.edu](mailto:PEpner@ChicagoBooth.edu)

Vickie Baselski, Ph.D.  
349 Riverbluff Place  
Memphis, TN 38103  
[vbaselski@uthsc.edu](mailto:vbaselski@uthsc.edu)

Robert H. Christenson, Ph.D.  
Director, Clinical Chemistry  
Laboratories & Professor of Pathology  
and Medical and Research Technology  
University of Maryland Medical Center  
22 South Greene Room N2W44 UMMS  
Baltimore, MD 21201-1544  
tel: 410 328-8672  
[rchristenson@umm.edu](mailto:rchristenson@umm.edu)

Nancy Cornish, M.D.  
The Pathology Center  
PO Box 24424  
Omaha, NE  
tel: 402-354-4554  
[cornish2@cox.net](mailto:cornish2@cox.net)

Colleen Kraft, M.D.  
Emory University  
1470 Crescent Walk  
Decatur, GA  
[cskendr@emory.edu](mailto:cskendr@emory.edu)

Ed Liebow, Ph.D.  
Health Research Leader  
& LMBP Project Manager  
Battelle Centers for  
Public Health Research and Evaluation  
1100 Dexter Avenue North, Suite 400  
Seattle, WA 98109  
tel: 206-528-3155  
[LiebowE@Battelle.org](mailto:LiebowE@Battelle.org)

Michael Saubolle, Ph.D.  
Pathology Department  
1111 E McDowell Road  
Phoenix, AZ 85006  
tel: 602-839-3485  
[mike.saubolle@bannerhealth.com](mailto:mike.saubolle@bannerhealth.com)

Robert Sautter, Ph.D.  
Carolinas Pathology Group  
P.O. Box 34455  
Charlotte, NC 28234-1039  
tel: 704-355-3476  
[robert.sautter@carolinashealthcare.org](mailto:robert.sautter@carolinashealthcare.org)

Susan Snyder, Ph.D.  
Economist & LMBP Program Officer  
CDC  
1600 Clifton Road MS-G23  
Atlanta, GA 30333  
tel: 404-498-2245  
[ssnyder@cdc.gov](mailto:ssnyder@cdc.gov)

Alice Weissfeld, Ph.D.  
Microbiology Specialists Inc  
8911 Interchange Dr  
Houston, TX 77054  
tel: 713-663-6888  
[alice@microbiologyspecialists.com](mailto:alice@microbiologyspecialists.com)

Donna Wolk, Ph.D.  
University of Arizona  
Dept of Pathology  
1501 N Campbell Ave  
PO Box 254049  
Tucson, AZ  
tel: 507-284-2511  
[dwolk@email.arizona.edu](mailto:dwolk@email.arizona.edu)

Peggy McNult, Staff  
ASM  
1752 N St, NW  
Washington, DC 20036  
tel: 202-942-9225  
[pmcnult@asmusa.org](mailto:pmcnult@asmusa.org)



# Review Questions from ASM Workshop

---

- **What practices are effective at increasing timeliness of providing targeted therapy for inpatients with diagnosed bloodstream infections (*positive blood cultures?*) to improve clinical outcomes (LOS, morbidity, mortality)?**
- What practices following specimen collection are effective at reducing false positive diagnoses of Urinary Tract Infections (UTI)?

# Sustainability

---

- Enlisting partners to support dissemination and uptake of best practices
- Topics in the pipeline
- Suggestions for panelists and feedback on topics: ASM
- **Formal recognition by CLIAC of need for a sustainable mechanism of applying systematic review methods and the use of evidence-based best practices in laboratory medicine.**

# Questions for the Committee

---

- Does the Committee agree that the LMBP approach to selecting and qualifying topics for evidence reviews is appropriate for identifying important evidence-based best practices in Lab Medicine?
- Would the Committee please comment on the list of new topics proposed for systematic reviews?
- Would the Committee please comment on other key topic areas, focusing on pre- and post-analytic stages of the total testing process, that it would like to see the LMBP Initiative add to its future calendar?
- Would the Committee consider formally recognizing the value of continuing the LMBP Initiative in a sustained fashion ?

# Thank You

rchristenson@umm.edu

diana.mass@asu.edu

---



For more information: [www.futurelabmedicine.org](http://www.futurelabmedicine.org)